Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. alleging securities fraud that negatively impacted investors between November 7, 2024, and July 8, 2025 [1][2] Group 1: Allegations of Fraud - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2] - It is alleged that the defendants overstated the demand for RxSight's products [2] - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [2] - Positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and has been recognized as one of the top securities litigation firms in the United States [4]

SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fiserv, Inc. (NYSE: FI) common stock between July 24, 2024 and July 22, 2025, both dates inclusive (the "Class Period"), have until September 22, 2025 to seek appointment as lead plaintiff of the Fiserv class action lawsuit. Captioned City of Hollywood Police Officers' Retirement System v. Fiserv, Inc., No. 25-cv-06094 (S.D.N.Y.), the Fiserv class action lawsuit charges Fiserv and certain ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS) between April 29, 2025 and June 22, 2025, inclusive. Should You Join This Class Action Lawsuit? If you purchased or acquired Hims securities, and/or would like to discuss your legal rights and options please visit Hims & Hers H ...

Core Viewpoint - Stitch Fix, Inc. is facing legal scrutiny regarding alleged false statements about its Freestyle business segment and significant insider stock sales totaling $132 million, which may have misled investors and inflated stock prices [1][2][3] Legal Developments - A U.S. District Court judge ruled that claims in a securities fraud lawsuit against Stitch Fix and its former CEO can proceed, indicating that the company may have misled investors about the Freestyle segment's impact on its core business [2] - The lawsuit alleges that from June 2020 to June 2022, Stitch Fix made false statements regarding the Freestyle segment, which purportedly led to artificially inflated stock prices [2] Financial Impact - Following the revelation in June 2022 that the Freestyle segment had negatively affected potential new Fix customers and the announcement of a 15% workforce reduction, Stitch Fix's stock price dropped by 27% [2]

Core Viewpoint - A lawsuit has been filed against Replimune Group, Inc. and its senior executives for potential violations of federal securities laws, following a significant decline in stock price after the FDA's response regarding the company's lead product candidate RP1 [1][2][5]. Company Overview - Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer treatment, with its lead product candidate being RP1 for melanoma [3]. Clinical Trial and Regulatory Issues - The company announced positive results from the IGNYTE Phase 1/2 clinical trial for RP1 in combination with nivolumab on June 6, 2024, and subsequently submitted a biologics license application (BLA) to the FDA based on these results [3][4]. - However, the FDA issued a Complete Response Letter on July 22, 2025, stating that the IGNYTE trial was not considered adequate for demonstrating effectiveness due to the heterogeneity of the patient population [5]. Stock Performance - Following the FDA's announcement, Replimune's stock price fell by more than 75% on July 22, 2025, reflecting investor reaction to the negative regulatory feedback [5].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between April 29, 2025, and June 23, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2] - It is alleged that this situation created a significant risk of termination of the collaboration between Hims and Novo Nordisk [2] - The defendants' positive statements regarding the company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing substantial recoveries for shareholders and has been recognized as a top securities litigation firm in the United States for seven consecutive years [4]

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP ("XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP" or the "Company") (NYSE: XIFR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP investors who were adversely affected by alleged securities fraud between September 27, 2023 and January 27, 20 ...

Core Viewpoint - A class action securities lawsuit has been filed against PepGen Inc. due to alleged securities fraud affecting investors between March 7, 2024, and March 3, 2025 [1][2]. Group 1: Allegations and Claims - The lawsuit claims that PepGen's lead product candidate, PGN-EDO51, was less effective and safe than previously represented [2]. - It is alleged that the phase two CONNECT2 study was dangerous or deficient for FDA approval purposes [2]. - The complaint suggests that PepGen was likely to halt the CONNECT2 study, and the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated [2]. - Defendants' public statements were claimed to be materially false and misleading throughout the relevant period [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 8, 2025, to request appointment as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the U.S. [4].

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Petco Health and Wellness Company, Inc. ("Petco" or the "Company") (NASDAQ: WOOF) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Petco investors who were adversely affected by alleged securities fraud between January 14, 2021 and June 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/petco-laws ...

NEW YORK, July 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Petco Health and Wellness Company, Inc. ("Petco" or the "Company") (NASDAQ: WOOF) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Petco investors who were adversely affected by alleged securities fraud between January 14, 2021 and June 5, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/petco-lawsuit-su ...